Prospective evaluation of community-acquired acute-phase hepatitis C virus infection

Clinical Infectious Diseases

Volumn 40, Issue 7, 2005, Pages 951-958

  Cox, Andrea L ^a,e   Netski, Dale M ^a   Mosbruger, Timothy ^a   Sherman, Susan G ^a   Strathdee, Steffanie ^b   Ompad, Danielle ^d   Vlahov, David ^d   Chien, David ^c   Shyamala, Venkatakrishna ^c   Ray, Stuart C ^a   Thomas, David L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; VIRUS ANTIBODY; VIRUS RNA;

ACUTE HEPATITIS; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY SCREENING; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD DONOR; CONTROLLED STUDY; CROSS INFECTION; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA; VIRUS TRANSMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HEPATITIS C; HUMANS; LIVER; MALE; PHYLOGENY; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VIRAL CORE PROTEINS; VIREMIA;

EID: 20144368978     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428578     Document Type: Article

References (31)

1. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72:341-4.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-5S.
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
4. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19):1-39.
5. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-14.
6. Cao J, Sullivan N, Desjardin E, et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997; 71:9808-12.
7. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-6.
8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
9. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98-104.
10. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21:639-44.
11. Garson JA, Tuke PW, Makris M, et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis C virus contaminated factor VIII concentrates. Lancet 1990; 336:1022-5.
12. Prince AM, Brotman B, Inchauspe G, et al. Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis. J Infect Dis 1993; 167:1296-301.
13. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406.
14. Shata MT, Tricoche N, Perkus M, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003; 314:601-16.
15. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 Suppl 1:S11-9.
16. Sherman SG, Fuller C, Shah ND, Strathdee SA. Transition to injection drug use among a sample of young injection drug users: the role of ethnicity. J Psychoactive Drugs (in press).
17. Linnen JM, Gilker JM, Menez A, et al. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription- mediated amplification. J Virol Methods 2002; 102:139-55.
18. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002; 40:2408-19.
19. Liu Z, Netski DM, Mao Q, et al. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol 2004; 42:4223-9.
20. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182:698-707.
21. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998; 23:403-5.
22. Hall TA. BioEdit: biological sequence alignment editor for Windows 95/98/NT, version 5.0.7.2001. Available at: http://www.mbio.ncsu.edu/RNaseP/ info/programs/BIOEDIT/bioedit.html. Accessed 1 September 2003.
23. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998; 14:817-8.
24. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39:783-91.
25. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-8.
26. Busch MP, Giachetti C, Conrad A, et al. Dynamics of very early HCV viremia [abstract 30]. In: Program and abstracts of the 8th International Symposium on Hepatitis C Virus and Related Viruses. 2001:30.
27. Koziel MJ, Wong DKH, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176:859-66.
28. Heller T, Sobao Y, Mizukoshi E, et al. HCV exposure in humans: stimulation of cellular, but not humoral immune responses in the absence of detectable viremia. Hepatology 2003; 38(Suppl. 1): abstract 57.
29. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992; 326:1399-404.
30. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998; 27:1213-9.
31. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug Use. Hepatology 1999; 29:590-6.